The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

Trial Profile

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs Saracatinib (Primary)
  • Indications Lymphangioleiomyomatosis
  • Focus Adverse reactions
  • Acronyms SLAM-1
  • Most Recent Events

    • 22 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Mar 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Apr 2015, according to to ClinicalTrials.gov record.
    • 23 Mar 2015 Status changed from recruiting to active, no longer recruiting, according to to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top